Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption
Fig 5
The proportion of per protocol participants showing positive ELISPOT assay responses during the 2012/1 and the 2007/1 studies.
For participants with values at week (wk) 0 in the 2012/1 and wk1 in the 2007/1 study (n = 23), the paired difference in proportions of participants with positive assay response was not statistically significant (-0.87; CI: -0.202, 0.028; p = 0.5). The two-sided p-value was derived from exact version of McNemar’s test. The 95% CI may not be valid as analysis is based on a small sample of data. The sample size was too small for a comparison of ELISPOT assay responses between wk28 in the 2012/1 study and wk52 in the 2007/1 study in participants that had data for both time points (n = 11). *Participants contributing data to the p-value.